About this item:

385 Views | 816 Downloads

Author Notes:

Correspondence: jorgecg@yahoo.com

See publication for full list of author contributions.

We thank NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH for the reagents kindly provided during our research.

Competing Interests: The authors have declared that no competing interests exist.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Subjects:

Research Funding:

Funded by Programa de Apoyo a la Investigación Científica y Tecnológica, Universidad Autónoma de Nuevo León (PAICYT-UANL) CS 804-11) (LGRM), Fondo de Investigación en Salud. Instituto Mexicano del Seguro Social (FIS-IMSS) FIS/IMSS/PROT/G12/1143 (JCG), Red Temática de Inmunología en Cáncer y Enfermedades Infecciosas del Consejo Nacional de Ciencia y Tecnología (INMUNOCANEI CONACYT) 253053 (CRP), The Southeastern Center for Emerging Biological Threats (FQ and RK), The Food and Drug Administration (FDA) Critical Paths Program U18FD004037-01 (FQ).

Keywords:

  • Science & Technology
  • Multidisciplinary Sciences
  • Science & Technology - Other Topics
  • IMMUNE-RESPONSES
  • RECOGNITION
  • EXPRESSION
  • DIAGNOSIS
  • BOVIS
  • CATTLE
  • GENES
  • TESTS
  • BCG
  • Mycobacterium tuberculosis
  • Enzyme-linked immunoassays
  • Tuberculosis
  • Serum proteins
  • Antibodies
  • Tuberculosis diagnosis
  • Mycobacterium bovis
  • Recombinant proteins

Detection of anti-HspX antibodies and HspX protein in patient sera for the identification of recent latent infection by Mycobacterium tuberculosis

Show all authors Show less authors

Tools:

Journal Title:

PLoS ONE

Volume:

Volume 12, Number 8

Publisher:

, Pages e0181714-e0181714

Type of Work:

Article | Final Publisher PDF

Abstract:

Mycobacterium tuberculosis is a pathogen causing tuberculosis (TB) a spectrum of disease including acute and asymptomatic latent stages. Identifying and treating latently-infected patients constitutes one of the most important impediments to TB control efforts. Those individuals can remain undiagnosed for decades serving as potential reservoirs for disease reactivation. Tests for the accurate diagnosis of latent infection currently are unavailable. HspX protein (α-crystallin), encoded by Rv2031c gene, is produced in vitro by M. tuberculosis during stationary growth phase and hypoxic or acidic culture conditions. In this study, using standard, and Luminex xMAP® bead capture ELISA, respectively, we report on detection of anti-HspX IgG and IgM antibodies and HspX protein in sera from acute and latent TB patients. For the antibody screen, levels of IgG and IgM antibodies were similar between non-infected and active TB patients; however, individuals classified into the group with latent TB showed higher values of anti-HspX IgM (p = 0.003) compared to active TB patients. Using the bead capture antigen detection assay, HspX protein was detected in sera from 56.5% of putative latent cases (p< 0.050) compared to the background median with an average of 9,900 pg/ml and a range of 1,000 to 36,000 pg/ml. Thus, presence of anti-HspX IgM antibodies and HspX protein in sera may be markers of latent TB.

Copyright information:

© 2017 Castro-Garza et al

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote